RETINOBLASTOMA PROTEIN AND PROLIFERATING-CELL NUCLEAR ANTIGEN EXPRESSION AS PREDICTORS OF RECURRENCE IN WELL-DIFFERENTIATED PAPILLARY THYROID-CARCINOMA
K. Omura et al., RETINOBLASTOMA PROTEIN AND PROLIFERATING-CELL NUCLEAR ANTIGEN EXPRESSION AS PREDICTORS OF RECURRENCE IN WELL-DIFFERENTIATED PAPILLARY THYROID-CARCINOMA, Journal of clinical oncology, 15(12), 1997, pp. 3458-3463
Purpose: We analyzed retinoblastoma protein (pRB) and proliferating-ce
ll nuclear antigen (PCNA) expression in primary tumors and recurrent l
esions of well-differentiated papillary thyroid carcinoma (PTC) to cla
rify the relationship between their expression and recurrent disease,
Patients and Methods: The study included 93 patients with PTC. No recu
rrent disease had developed in 60 patients within 10 years after surge
ry (group N), Thirty patients in whom recurrent disease had developed
after surgery were enrolled in group R. Levels of pRB and PCNA express
ion were quantified using the CAS 200 system (Cell Analysis Systems, E
lmhurst, IL) following immunohistochemical staining, Results: Mean pRB
expression level in the primary tumors in group R was significantly l
ower than that in group N (P < .0001). pRB expression in the rumors wi
th ct diameter vp to 20 mm was significantly lower than that in tumors
larger than 20 mm in group R (P < .01). There were no significant dif
ferences in the levels of expression of PCNA in the primary tumors bet
ween group N and group R, Univariate analysis demonstrated that the di
sease-free survival was significantly correlated with pN category, pRB
, and PCNA expression level, The subgroup with high-level expression o
f pRB (> 25%) showed significantly long disease-free survival (P < .00
1). Furthermore, the subgroup with low level expression of PCNA (< 35%
) showed significantly longer disease-free survival (P < .05), Multiva
riate analysis showed pRB expression and pN category to be independent
prognostic factors for disease free survival in PTC, Conclusion: pRB
expression level can be used as a reliable predictor for recurrence of
PTC. (C) 1997 by American Society of Clinical Oncology.